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Abstract
Pain is a common symptom in people with autosomal dominant polycystic kidney disease
(ADPKD), but it is assessed and reported inconsistently in research, and the validity of the
measures remain uncertain. The aim of this study was to identify the characteristics, con-
tent, and psychometric properties of measures for pain used in ADPKD. We conducted a
systematic review including all trials and observational studies that reported pain in people
with ADPKD. Items from all measures were categorized into content and measurement
dimensions of pain. We assessed the general characteristics and psychometric properties
of all measures. 118 studies, we identified 26 measures: 12 (46%) measures were devel-
oped for a non-ADPKD population, 1 (4%) for chronic kidney disease, 2 (8%) for polycystic
liver disease and 11 (42%) specifically for ADPKD. Ten anatomical sites were included, with
the lower back the most common (10 measures [39%]), four measurement dimensions
(intensity (23 [88%]), frequency (3 [12%]), temporality (2 [8%]), and sensory (21 [81%]), two
pain types, nociceptive including visceral (15 [58%]) and somatic (5 [20%]), and neuropathic
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(2 [8%]), and twelve impact dimensions, where the most frequent was work (5 [31%]). The
validation data for the measures were variable and only the ADPKD Impact Scale reported
all psychometric domains. The measures for pain in ADPKD varied in terms of content and
length, and most had not been validated in ADPKD. A standardized psychometrically robust
measure that captures patient-important dimensions of pain is needed to evaluate and man-
age this debilitating complication of ADPKD.
Introduction
Pain is a debilitating symptom that is experienced by more than 60% of people with autosomal
dominant polycystic kidney disease (ADPKD) by the age of 40 years old [1]. The progressive
growth of cysts in the kidneys and cyst complications including infection and rupture [2] can
cause extreme acute or persistent chronic pain [3] if pain lasts for longer than 4–6 weeks [4].
ADPKD-related pain impacts on sleep quality and physical activity, impairs well-being and
overall quality of life due to its recurrent nature and severity [5], necessitating regular analge-
sics in up to 30% of people with ADPKD [6, 7]. People with ADPKD report pain in a range of
sites including the lower back (71%), abdomen (61%), head (49%), and chest (30%) [8], and
the onset of pain can be sudden and unpredictable [9]. Cyst-related pain is often persistent
and aggravated by standing and walking and the source of pain in ADPKD is often unable to
be determined compared with other general pain [10].
The Standardized Outcomes in Nephrology-PKD (SONG-PKD) initiative identified pain as
one of the four core outcomes in PKD [11], defined as outcomes of critical importance to all
key stakeholders, including patients/caregivers, health professionals, policy makers/funders
from recently completed consensus workshop. Pain is the only patient-reported outcome
(PROM) in the core outcome set, which was highly prioritised due to its significant and
adverse impact on daily and social activities [12]. Despite being identified as a critically impor-
tant outcome [13], pain is often under recognized and poorly managed [13]. Although there
are strategies available to manage pain, including non-pharmacologic treatments (manage-
ment of diet and lifestyle), analgesics and surgery [14], people with ADPKD still report pain
and there is no a systematic approach for the clinical assessment of pain in this setting [3].
Despite its critical importance and being highly prioritized by all stakeholders, pain was
reported in only 16 (24%) of randomized trials involving people with ADPKD according to a
recent systematic review [15]. Pain has been identified as a core outcome in ADPKD, which
means it is to be measured and reported in all trials involving people with ADPKD, using a
consistent, validated outcome measurement tool. The aim of this study was to identify the con-
tent, general characteristics, and validity of measures used to assess pain in people with
ADPKD, to select a robust and feasible outcome measure to use in all clinical trials in this set-
ting. The identification of a suitable measure to capture crucial aspects of pain will ensure an
accurate assessment and better understanding of factors associated with pain, and identify
interventions targeting to manage pain in people with ADPKD.
Materials and methods
Selection criteria
We searched for all study designs (interventional and non-interventional studies) that involved
patients aged at least 18 years with ADPKD and included a patient-reported outcome measure
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(questionnaire) that assessed any type of pain. Global measures (e.g. a composite measure for
health-related quality of life or health status that assessed multiple domains including pain)
were included if they reported a pain-specific item, even if they were not designed for ADPKD
population. However, only items related to pain were assessed. Studies published in peer-
reviewed journals without language restrictions were included. Abstract-only citations were
included only if we were able to extract sufficient information about the measure (characteris-
tics and content) used to assess pain.
Study sources and measures
We conducted searches in MEDLINE, Embase, PsycINFO and the CKT register from database
inception to February 2020. Google Scholar and reference lists of relevant studies and reviews
were also searched. The search strategies are provided in S1 Table. Three authors (PN, EH,
AT) independently screened all abstracts and excluded those not meeting the inclusion crite-
ria, then assessed remaining full-text articles for eligibility. Any uncertainties and disagree-
ments about the inclusion of articles were discussed until we reached consensus.
Data extraction and analysis
We extracted the following characteristics from each study included: publication year, country,
study design, sample size, type of intervention (if applicable), measure used to assess pain and
study duration. To summarize characteristics for the measures identified, PN and EH referred
to the source study and key references to extract the following information: response format
scale, number of items, recall period, cost of license to use the measure, completion time, lan-
guage and number of studies that used the measure. PN performed a distinct search for valida-
tion studies for each measure and extracted psychometric data in people with ADPKD, using
the Consensus-based Standards of health Measurement Measures-Core outcome measures in
Effectiveness Trials (COSMIN-COMET) [16]. The data were independently cross-checked by
authors EH and AB.
Dimensions of pain
To determine the dimensions assessed in the measures of pain, PN and EH initially extracted
all items (questions) on pain, including items from the pain subscale of global measures. The
range of items were sorted into dimensions inductively derived. The dimensions identified
were the site of pain, measurement (e.g. frequency, intensity), type of pain, and impact of pain.
The frequency of each dimension was recorded.
Assessment of psychometric properties
As recommended by COSMIN-COMET [16] guidelines, we examined the available evidence
for validity and reliability of the identified measures by examining psychometric properties:
content validity, structural validity, criterion validity, reliability including test-retest and inter-
nal consistency, measurement error, cross-cultural validity and responsiveness.
Results
Characteristics of studies
We identified 4806 potential relevant citations after removing the duplicates. We included 118
studies involving a total of 12,566 participants with ADPKD across 35 countries. Of the
included studies, 36 (30%) were interventional studies and 82 (70%) were non-interventional
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studies. The search results are shown in Fig 1. The study characteristics and measures used to
assess pain are provided in S2 and S3 Tables. The PRISMA Checklist is provided in S6 Table.
Characteristics of the measures
Across the 118 studies, there were 26 different patient-reported outcome measures used to
assess pain. Of these, 16 (62%) were established measures and 10 (38%) measures were
designed by the authors for use in their study only, without validation. Twelve (46%) measures
were developed for a non-ADPKD population, one (4%) for all stages of chronic kidney dis-
ease, two (8%) for polycystic liver disease and 11 (42%) were developed for people with
ADPKD (Fig 2). Eleven (42%) measures were developed specifically to assess general pain and
15 (58%) assessed broader outcomes such as quality of life and symptoms, in which pain was a
Fig 1. PRISMA flowchart.
https://doi.org/10.1371/journal.pone.0252479.g001
Fig 2. Type of measures used to assess pain in patients with ADPKD.
https://doi.org/10.1371/journal.pone.0252479.g002
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subscale. Regarding measures that were not specifically designed to assess pain, number of
items ranged from one (n = 4 measures [17–20]), two (n = 3 measures [21–23]), three (n = 5
measures [24–28]), four (n = 1 measure [29]), five (n = 1 measure [30]), and 10 items (n = 1
measure [31]).
Type of measures used to assess pain in patients with ADPKD. Abbreviations and defini-
tions: non-ADPKD, measures developed for patients without autosomal dominant polycystic
kidney disease; CKD, measures developed for patients with chronic kidney disease; PLD, mea-
sures developed for patients with polycystic liver disease; ADPKD, measures developed for
patients with autosomal dominant polycystic kidney disease.
The 36-Item Short Form Health Survey (SF-36) was the most frequently used measure
reported in 16 (33%) studies, followed by Visual Analog Scale (VAS) in 11 (22%) studies, Euro-
Qol-5 Dimension Questionnaire (EQ-5D) in seven (14%) studies and Gastrointestinal ques-
tionnaire (GI-Q) in six (12%) studies. The time taken for completion of each measure ranged
from two minutes to 30 minutes.
The number of items in the questionnaires varied from nine (Short-form Brief Pain Inven-
tory (BPI-SF)) to 80 (Kidney Disease Quality of life—Short Form (KDQOL-SF)). The recall
period ranged from the day of assessment to 10 years. Most of the measures (23, 88%) were
free of charge for non-commercial use, some of which required study registration. Characteris-
tics of measures and frequency of use are provided in Table 1.
Dimensions of pain
Pain-related items from the measures were classified into four content dimensions [43], which
capture the site of pain (e.g. abdomen, lower back, thorax, head and face, generalized body and
non-specified), measurement (intensity, frequency, temporality and sensory), type (nocicep-
tive and neuropathic pain) and impact (life participation, sleep and mental).
The measures assessed 10 sites dimensions: abdomen including general abdomen (8 [31%]
measures), upper abdomen (4 [15%]), lower abdomen (2 [8%]), flank (7 [27%]); lower back
(10 [39%]); thorax including chest (1 [4%]) and rib cage (2 [8%]); head and face (3 [12%]); gen-
eralized body (8 [31%]); and non-specified pain (9 [35%]). The measures assessed four mea-
surement dimensions: intensity (23 [88%]), frequency (3 [12%]), temporality (2 [8%]), and
sensory (21 [81%]); and two dimensions for type: nociceptive including visceral (15 [58%])
and somatic (5 [20%]); and neuropathic (2 [8%]).
The measures assessed 12 impact dimensions that were reported only in the established
measures: life participation including daily activity (4 [25%]), social activity (3 [19%]), work (5
[31%]), walking ability (2 [13%]), physical function (2 [13%]), and strenuous physical activity
(1 [6%]), and one dimension for sleep (3 [19%]). The measures assessed mental impact includ-
ing mood (2 [13%]), bother (2 [13%]), anxiety (1 [6%]), affective (2 [13%]), and enjoyment of
life (2 [13%]). None of the author-developed measures assessed impact dimensions. The defi-
nitions of each dimension are given in Tables 2–4. Dimensions of pain assessed by measures
are provided in S5 Table.
Psychometric properties
The validity and reliability for each measure in people with ADPKD is shown in S4 Table. Of
the 16 measures, only two (13%) were validated in the ADPKD population. A summary of the
psychometric data for each of these measures is shown in Table 5. The validation data for the
measures were variable and only one measure, the ADPKD Impact Scale (ADPKD-IS) [24],
provided information across all psychometric domains. The Polycystic Liver Disease question-
naire (PLD-Q) [31] was also evaluated for psychometric properties in people with ADPKD.
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The ADPKD-IS was a 18 items measure created specifically for the ADPKD population,
and the development of the measure included quantitative and qualitative studies, with the
involvement of clinicians with expertise in ADPKD and people with ADPKD [24]. Confirma-
tory Factor Analysis supported a three-factor structure rather than the hypothesised two-factor
structure, with the addition of four domain-independent items that were retained in the mea-
sure. Item discrimination for all items was adequate and each item was adequately correlated
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- - Contact author - Yes No No No English 1 (2%)
(-) Not stated, unclear, or unable to ascertain
� The name of questionnaire was extracted from the protocol, since it was not clearly stated in the primary publication (only “Pain questionnaire” was reported)
# Abstract
! More than one studied referred to the same publication; Y/N: Questions requiring yes/no answers. Note: The language is referred to the language that was used in the
studies rather than the available languages for the measures.
Abbreviations: KDQOL-SF: Kidney Disease Quality of life—Short Form; GI-Q: Gastrointestinal questionnaire; VAS: Visual Analog scale; SF-36: Medical Outcomes
Study Form, 36 items health survey; ADPKD-IS: ADPKD Impact Scale; PLD-Q: Polycystic Liver Disease questionnaire; EQ-5D: European Quality of Life-5 Dimension
Questionnaire that may include a VAS scale for pain; EORTC QLQ-C30: European Organization for Research and Treatment of Cancer quality of life questionnaire
core-30; BPI-SF: Short-form Brief Pain Inventory; SF-MPQ: Short Form of the McGill Pain Questionnaire; MPQ-DV: McGill Pain Questionnaire (Dutch version); SF-
12: Health Survey Short Form 12; GSRS: Gastrointestinal Symptom Rating Scale; HAM-D: The Hamilton Depression Rating Scale; Wisconsin BPS: Modified version of
Wisconsin Brief Pain Survey.
a Upon registration for version 2, users can obtain a quote for the license fee that applies to their project; version 1 can be obtained for free
b VAS scale was clearly reported to assess pain in all studies except Qian 2015 [42]. VAS item with open-ended response questions vary
c This author-developed instrument was reported in two studies as ADPKD-related pain
d This author-developed instrument was reported in two studies as Kidney pain score.
https://doi.org/10.1371/journal.pone.0252479.t001
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through correlations between changes in the physical domain score and changes in pain inten-
sity measured by pain ratings in the BPI-SF. As predicted, higher scores on all domains were
associated with more advanced disease stage. Correlations between ADPKD-IS domains and
summary scores on the Health Survey Short Form 12 (SF-12) indicated sufficient concurrent
validity. The ADPKD-IS has high test-retest reliability and high internal consistency, both
overall and within each domain [24].
The PLD-Q was not created for ADPKD patients without polycystic liver disease, however
people with ADPKD were included in the validation study. The PLD-Q was designed based on
qualitative and quantitative studies, including two validation studies. Factor analysis supported
a unidimensional structure of the measure. As expected, ADPKD patients scored higher for
pain than healthy controls but lower than patients with PLD, supporting discriminant validity














Flank Chest Rib cage (behind/
below)^
Walsh 2012 [41] •
� Lower back pain was attributed to kidney pain
^ Pain behind or below the rib cage was attributed to liver pain
# Abstract
! More than one studied referred to the same publication
• Data were available for the selected field.
a Measure reported kidney pain without other specific description. According to the definition reported in other studies, kidney pain was described as flank, back and
abdominal pain
b Generalized pain included muscle aches
c Generalized pain included bodily pain
d Qian 2015 [42] non-specified if VAS was a “pain specific instrument”, and no any additional information were reported about pain
e Other pain was assessed as non-specified pain
f Chrispijn 2013 [27] used VAS scale used to assess pain to record abdominal pain
g Kucuk 2016 [44], Dunn 2000 [45], Lee 2003 [46], Lee 2004 [47] reported that patients had abdominal pain and flank pain. Although no further information were
reported about VAS scale used to assess pain, we can assume that authors used this instrument to assess abdominal and flank pain
h Dunn 2001 [48] reported that patients had abdominal pain. Although no further information were reported about VAS scale used to assess pain, we can assume that
authors used this instrument to assess abdominal pain
i Lipke 2007 [49], Yu 2018 [50] reported that patients had kidney pain. Although no further information were reported about VAS scale used to assess pain, we can
assume that authors used this instrument to assess kidney pain
j Rehman 2001 [51] reported that patients had flank pain with or without back pain
k Sulikowski 2006 [52] reported that patients had back and abdominal pain. Although no further information were reported about VAS scale used to assess pain, we can
assume that authors used this instrument to assess abdominal and back pain
l Upper abdomen pain included epigastric soreness and right upper abdomen quadrant pain
m Upper abdomen pain was reported as right upper abdomen pain, behind or below the rib cage, and was attributed to liver pain
n Rib cage pain was reported as pain or pressure in the rib cage
o Pain location was not reported
p Generalized pain included heartburn
q Generalized pain included bodily pain and heartburn
r Pain location was not reported
s VAS item with open-ended response questions vary
t Generalized pain included heartburn and epigastric pain.
https://doi.org/10.1371/journal.pone.0252479.t002
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Table 3. Dimensions of pain assessed by measures: Measurement and type of pain.
Measure Measurement Type
Intensity Frequency Temporality� Sensory§ Nociceptive Neuropathic
Visceral^ Somatic$
Established measures
SF-36 [22]s • •
VAS s,ç, £ • • •
EQ-5D [20]s • •
GI-Q [27]a,q • • •
KDQOL-SF [29]b,s,t • • • •
ADPKD-IS [24] •
PLD-Q [31]c,r • • • •
EORTC QLQ-C30 [23]s • •
BPI-SF [32]d,u • • •
MPQ-DV [33]¥ • •
SF-MPQ-2 [34]e • • •
SF-12 [18] •
GSRS (Revised) [28]f,r • • • •
HAM-D [19]g,r,t • • • •
Wisconsin BPS (Revised) [6]h,r,z • • • • •
GI-Q (Revised for PLD) [35]i,q • • •
Author-developed measures
D’Agnolo 2016 [36]#! • •
D’Agnolo 2017 [37]!j
Torres 2012 [7]! • •
Torres 2011 [38]!k
Suwabe 2013 [21]l,q,r • • •
Suwabe 2017 [25]m,q,r,s • • •
Haseebuddin 2012 [39]s,v • •
Iliuta 2019 [26]n,r • • •
Sakuhara 2015 [17]o,r • • •
Taylor 2005 [30]p • •
Abraham 2015 [40]s • •
(Continued)
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and the European Organization for Research and Treatment of Cancer quality of life question-
naire core-30 (EORTC QOL30) symptom burden score, as well as between the total PLD-Q
and the VAS global health scale. Test-retest reliability and internal consistency were both high.
Discussion
The measures of pain differed in content, length, response format scale, number of items,
recall period, cost of licence, completion time and available psychometric proprieties. Our
Table 3. (Continued)
Measure Measurement Type
Intensity Frequency Temporality� Sensory§ Nociceptive Neuropathic
Visceral^ Somatic$
Walsh 2012 [41]s • •
� Temporality included continuous, recurring, irregular, intermittent pain
§ Sensory included the sensation of pain as burning, sharp, intense, aching
^Visceral pain included injury/damage to internal organs (liver, kidney), abdomen, chest, epigastric soreness, heartburn
$ Somatic pain included injury/damage to muscle, rib cage, headaches, sprains, cramps
# Abstract
! More than one studied referred to the same publication
£ VAS item with open-ended response questions vary
• Data were available for the selected field.
a Visceral pain was defined as lower and upper abdominal pain and heartburn
b Visceral pain was defined as chest pain. Somatic pain was defined as cramps
c Visceral pain was defined as back, flank and abdominal pain. Somatic pain was defined as pain or pressure in rib cage
d Somatic pain was defined as headaches, sprains
e Sensory descriptors of pain included:1) continuous pain descriptors (throbbing, cramping, gnawing, aching, heavy and tender pain); 2) intermittent pain descriptors
(shooting, stabbing, sharp, splitting, electric-shock and piercing pain); 3) predominantly neuropathic pain descriptors (hot-burning and cold-freezing pain, pain caused
by light touch, itching, tingling or pins and needles, numbness
f Visceral pain was defined as right upper quadrant, back, flank pain and epigastric soreness
g Visceral pain was defined as back pain. Somatic pain was defined as muscle pain, headaches and cramps
h Visceral pain was defined as back and abdominal pain
i Visceral pain was defined as lower and upper abdominal pain and heartburn
j Visceral pain was defined as liver (defined as right upper quadrant pain, behind or below the rib cage) and kidney pain (defined as back, flank and abdominal pain)
k Visceral pain was defined as kidney pain
l Visceral pain was defined as heartburn
m Visceral pain was defined as heartburn
n Visceral pain was defined as back, flank and abdominal pain
o Visceral pain was defined as back and abdominal pain
p Visceral pain was defined as back, flank and abdominal pain. Somatic pain was defined headaches
q Heartburn was assessed as sensory pain
r Abdominal distension/fullness/ heavy feelings in abdomen were assessed as sensory pain
s Bodily/generalized pain was assessed as sensory pain
t Cramps and was assessed as sensory pain
u Sprains was assessed as sensory pain
v Pain intensity was reported as degree of subjective pain relief
z Neuropathic pain was reported as radicular pain
ç Rehman 2001 [51] reported intermittent pain
¥ Sensory descriptors of pain included temporal, spatial, punctate pressure, incisive pressure, constrictive pressure, traction pressure, thermal, dullness, stiffness,
continuity.
https://doi.org/10.1371/journal.pone.0252479.t003
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analysis showed that only 119 studies in people with ADPKD measured pain, and of these 36
(30%) were randomized trials. Across these studies, 26 different measures were used, which
demonstrates inconsistencies in how pain in ADPKD is assessed. Only 11 (42%) were devel-
oped for an ADPKD population, of which most (eight measures) were non-validated and
Table 4. Dimensions of pain assessed by measures: Impact of pain�.
Measure Impact


































• • • • • • • • •
GI-Q (Revised for
PLD) [35]
� No author-developed measures reported impact as a dimension of pain
$ Work included both work outside the home and housework
£ VAS item with open-ended response questions vary
• Data were
available for the selected field. Note: Physical function included normal or mild exercises.
a Daily activity included the patient’s need to modify lifestyle
b Social activity included relations with others and hobbies
c Affective descriptors of pain included tiring-exhausting, sickening, fearful and punishing-cruel
d Affective descriptors of pain included tension, autonomic, fear, punishment.
https://doi.org/10.1371/journal.pone.0252479.t004
Table 5. Development/validation data on psychometric properties.
Measure/Psychometric proprerty Validity Reliability
Content Construct Criterion Test-retest Internal consistency
Convergent Discrimination Predictive Concurrent
ADPKD-IS [24] • • • • • •
PLD-Q [31] • • • • • •
Note: Validation studies were excluded if they were not available in full, were for a translation of the original measure or were not written in English
• Data were available for the selected field.
https://doi.org/10.1371/journal.pone.0252479.t005
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developed de novo for the author’s study. More than half of the measures (58%) were not
designed specifically for pain. Over one-third of measures (35%) had at least 15 items and four
(15%) measures had an estimated completion time of more than five minutes. The sites of pain
included lower back and non-specified region/s, and the measurement properties including
intensity and types were reported in at least one-third of the measures. The impact of pain on
life participation and mental wellbeing were assessed in 12 (75%) measures, and all in estab-
lished measures only.
Evidence for psychometric validation of the measure for pain in the ADPKD was available
for only two measures. Two measures [24, 31], including one that was designed for PLD,
assessed psychometric robustness in ADPKD based on the COSMIN-COMET properties. One
measure reported data on all psychometric domains in ADPKD. Both measures had more
than 10 items and costs of licence were not reported, and they might not be feasible as a core
outcome measure or applicable in low income countries. The suitability of other measures to
evaluate pain in ADPKD remains unclear as content validity and internal consistency may not
be transferable across different patient populations because of range of clinical conditions and
treatments. Pain is infrequently evaluated as a separate construct in ADPKD, and often it is
incorporated as an item of health-related quality of life. Our findings suggest that pain has
been not adequately assessed and a standardized and psychometrically valid measure that
addresses key dimensions of pain in ADPKD is needed. However, it is still unclear if a new
ADPKD-specific measure may be more appropriate compared to the current measures.
The current measures show a very broad range of dimensions in terms of the site of pain,
measurement properties, type and impact. Pain complaints are complex and some patients
with ADPKD develop a so called chronic pain syndrome, including chronic pelvic pain syn-
drome or irritable bowel syndrome, that can exacerbate pain. Many of these measures do not
reflect the dimensions of pain important to people with ADPKD, are burdensome to adminis-
ter and complete, and lack evidence to support the psychometric properties. It remains unclear
whether some of these measures were able to discriminate between kidney specific and not
kidney specific pain, and central sensitization and mental status have not been adequatelly
investigated. The pain subscale in the SF-36 questionnaire, which was the most commonly
used measure, included only two questions and it is unclear if they assess the dimensions of
critical importance to people with ADKPD, and the specific subscale has not been validated.
Pain should be collected in “real-time” using tools such as mobile apps, especially because peo-
ple with ADPKD have both a chronic level of pain and experience acute pain episodes which
have to be adequately distinguished.
This review yields a comprehensive assessment of measures that have been used to evaluate
pain in people with ADPKD. However, there are some potential limitations. We did not
include study protocols and unpublished studies, so some measures of pain used in people
with ADPKD may not have been captured and other measures could be potentially adequate
to use in ADPKD setting (e.g. the Central Sensitization Inventory [53]). We searched for pri-
mary validation studies and did not conduct systematic search for the validation studies for
each measure. We recognize that it would not be possible to find all relevant studies that
reported validation data for all the measures, and there are only limited data on the psycho-
metric properties because of the limited number of measures validated in ADPKD. We
acknowledge that people with ADPKD experience frequently adaptation to recurrent acute
and chronic pain and, despite the severity of symptoms, the real impact of pain could be
underestimated in this setting.
To improve consistency in reporting patient-important outcomes such as pain, core outcome
measures for pain have been established in other non-CKD patient populations. In rheumatol-
ogy, as part of the Outcome Measures in Rheumatology (OMERACT) [54] initiative, focus
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groups and interviews were conducted with patients and clinical researchers to establish patient-
relevant outcome domains and to identify a measure that captured all critical aspects to assess
pain in patients with hip or knee osteoarthritis [55]. However, there were no optimal existing
measures in osteoarthritis and a new measure was developed addressing intensity, frequency,
impact on quality of life and sleep, and the extent of worry and frustration on pain recurrence,
which were of importance to patients [56]. Several PROMIS pain measures have been established
and demonstrated to be psychometrically robust in other chronic conditions, such as cancer [57].
Although these measures have not been validated in ADPKD and did not provide further dimen-
sions, the PROMIS item bank for pain can be considered as a reference for the list of possible
questions to evaluate in each dimension, considering intensity and life participation as essential
dimensions also in our setting. The impact of pain in sexual intercourse and central sensitization
have not been explored and may be included in the future research.
As part of the SONG-PKD initiative, pain was established as a core outcome based on a
consensus among patients, caregivers and health professionals [12]. This systematic review is
the first phase in identifying or developing a standardized, validated measure for pain, and
provides detailed and comprehensive information about the domains to potentially address
when measuring pain in people with ADPKD. Subsequent work will be based on the
COMET-COSMIN framework [16] for establishing core patient-reported outcome measures
and will involve an international consensus workshop with patients with ADPKD and health
professionals, to discuss potential patient-reported outcome measures for pain to capture all of
the relevant domains that are considered important to patients. The proposed measure will be
piloted and validated in people with ADPKD, to assess if the measure is appropriate and reli-
able to evaluate pain in this setting. A standardized and validated measure to assess pain in
people with ADPKD will improve consistency in the assessment and reporting of pain in
research, and may lead to better pain management and patient outcomes.
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